Fig. 1.

Effect of treatment with tetrac and Tetrac NP on PANC-1 tumor xenograft size, weight, and hemoglobin content. a Effect of unmodified tetrac (10 mg/kg daily, i.p.) or Tetrac NP (1 mg/kg daily, i.p.) on PANC-1 cell xenograft volumes. Volumes were measured daily or every other day. PANC-1 cells were implanted on day −15, and drug treatment was started on day 0. Significant diminution in xenograft volumes was seen in both tetrac and Tetrac NP treatment groups by days 5–6 (both flanks, P < 0.05), and by days 7–15, both treatment groups showed further size reductions significantly different from the untreated xenografts (P < 0.01). Xenograft volumes continued to increase in the control group to day +15. b Effects of tetrac or Tetrac NP on the weights of PANC-1 xenografts at the termination of the study (day +15). Treatment was as shown in (a). A decrease in xenograft weights in the animals exposed to either tetrac or Tetrac NP was observed (*P < 0.05). c Actions of unmodified tetrac or Tetrac NP on angiogenesis in PANC-1 cell xenografts, as measured by hemoglobin content of the tumors at the time of animal sacrifice. Hemoglobin content of the xenografts was reduced in the presence of both tetrac and Tetrac NP (*P < 0.05). Effect of treatment with tetrac and Tetrac NP on MPanc96 tumor xenograft weight and hemoglobin content. d Effects of tetrac or Tetrac NP on the weights of MPanc96 xenografts at the termination of the study (day +15). A decrease in xenograft weights in the animals exposed to either tetrac or Tetrac NP was observed (*P < 0.05). e Actions of unmodified tetrac or Tetrac NP on angiogenesis in MPanc96 cell xenografts, as measured by hemoglobin content of the tumors at the time of animal sacrifice. Hemoglobin content of the xenografts was reduced in the presence of both tetrac and Tetrac NP (*P < 0.05)